Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...
Sunderland Echo on MSN
Washington woman's Everest trek to raise money in memory of much loved friend who passed away
Karen Joynson raised money for two charities close to her heart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results